Therefore, class III BRAF mutations are associated with increased sensitivity to EGFR inhibitors and prolonged survival after treatment in patients with colorectal cancer,38,40,41 a phenomenon that is in stark contrast to class I BRAF mutations, as colorectal cancer patients with class I mutations respond poorly to EGFR inhibitors and have less favorable survival outcomes after treatment. Here, EGFR is linked to colorectal cancer.